| |
| |
|
| Insider
Information: |
Bentsur Ron |
| Relationship: |
Chairman & CEO, Direct... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
4,184,530 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$52,263 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
4,184,530 |
|
|
| Total
Value |
$52,263 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
Chief Executive Office... |
2015-04-06 |
777,209 |
|
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
CEO |
2007-08-21 |
20,101 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Director |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
Beyond Air Ord Shs |
XAIR |
Director |
2023-03-20 |
144,736 |
|
0 |
Premium* |
|
|
Nuvectis Pharma, Inc. |
NVCT |
Chairman & CEO, Direct... |
2024-03-18 |
3,242,484 |
2022-02-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
150 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KERX |
Keryx Biopharmaceuticals ... |
officerTitle |
• – – |
2003-06-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,491 |
|
- |
|
| XTLBY |
XTL Biopharmaceuticals Lt... |
CEOOfficer |
• – – |
2006-08-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,222 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
CEOOfficer |
• – – |
2009-05-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
206,661 |
|
- |
|
| STML |
Stemline Therapeutics Inc |
Director |
– • – |
2013-01-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,252 |
|
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2017-03-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
260,079 |
|
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEOOfficer |
• • – |
2022-02-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,565,459 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2009-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
392,221 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2010-03-23 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
642,221 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2011-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
380,572 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2012-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
392,281 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2013-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
503,046 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2013-10-04 |
4 |
A |
$0.00 |
$0 |
D/D |
400,000 |
859,065 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
26,611 |
885,676 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
500,000 |
1,255,977 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2015-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
67,375 |
784,375 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Director |
– • – |
2015-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
17,285 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Director |
– • – |
2017-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
27,285 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Director |
– • – |
2018-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
13,158 |
40,443 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Director |
– • – |
2019-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
65,443 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Director |
– • – |
2020-06-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(66,346) |
0 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
2,945,459 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
210,000 |
3,225,459 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• – – |
2009-05-22 |
4 |
B |
$0.37 |
$29,767 |
D/D |
80,000 |
286,661 |
2.74 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2009-06-23 |
4 |
B |
$0.90 |
$4,997 |
D/D |
5,560 |
292,221 |
2.73 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Accounting Officer |
• – – |
2006-03-29 |
4 |
OE |
$1.10 |
$38,500 |
D/D |
35,000 |
49,991 |
|
- |
|
150 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
